Vermillion (VRML) Reports Strong Top-Line Results for VASCLIR

Vermillion, Inc. (Nasdaq: VRML), reports positive top-line results from the intended use study for its peripheral artery disease (PAD) blood test, VASCLIR. The goals of the study were to validate the markers described in earlier publications (Circulation, 2007 and Vascular Medicine, 2008) and to develop and validate a biomarker panel applicable to the intended use population.

Key takeaways from the study include the following:

• The individual biomarkers beta 2 Microglobulin (b2m), cystatin C, and hsCRP, each has statistically significant different levels between PAD subjects and non-PAD subjects (p<.001).
  
  
• As in the previous study, these biomarkers also showed correlation to the ankle-brachial index (ABI), each with p<.001.
  
  
• Preliminary assessment of candidate biomarker panels derived in the intended use population demonstrated an odds-ratio of approximately 7.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Synaptics CFO resigns amid pending ON Semiconductor merger
• Robo.ai names Hao Wang of Changer.ae to its board of directors
• Docebo raises share buyback price to $25, extends offer deadline